Bots, editor, reviewer, Administrators
13,951
edits
No edit summary |
No edit summary |
||
Line 1,125: | Line 1,125: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2025-05-22T17:33:23Z", | ||
"briefDesignDescription" : "Aspirin for ASCVD 1° prevention if age >70", | "briefDesignDescription" : "Aspirin for ASCVD 1° prevention if age >70", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800722", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1800722", | ||
Line 1,138: | Line 1,138: | ||
"published" : "2018-09-16", | "published" : "2018-09-16", | ||
"pageName" : "ASPREE", | "pageName" : "ASPREE", | ||
"diseases" : " | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : "ASPREE", | "abbreviation" : "ASPREE", | ||
"title" : "Effect of aspirin on disability-free survival in the healthy elderly", | "title" : "Effect of aspirin on disability-free survival in the healthy elderly", | ||
Line 1,277: | Line 1,277: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2025-05-22T17:32:42Z", | ||
"briefDesignDescription" : "DOAC, VKA, antiplatelets after PCI with stent and AF", | "briefDesignDescription" : "DOAC, VKA, antiplatelets after PCI with stent and AF", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1817083", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1817083", | ||
Line 1,290: | Line 1,290: | ||
"published" : "2019-04-18", | "published" : "2019-04-18", | ||
"pageName" : "AUGUSTUS", | "pageName" : "AUGUSTUS", | ||
"diseases" : "Coronary | "diseases" : "Coronary Artery Disease;Atrial Fibrillation", | ||
"abbreviation" : "AUGUSTUS", | "abbreviation" : "AUGUSTUS", | ||
"title" : "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", | "title" : "Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation", | ||
Line 2,208: | Line 2,208: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2025-05-22T17:32:54Z", | ||
"briefDesignDescription" : "Low-dose MTX for secondary prevention of CAD", | "briefDesignDescription" : "Low-dose MTX for secondary prevention of CAD", | ||
"fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1809798", | "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/NEJMoa1809798", | ||
Line 2,221: | Line 2,221: | ||
"published" : "2018-11-10", | "published" : "2018-11-10", | ||
"pageName" : "CIRT", | "pageName" : "CIRT", | ||
"diseases" : "Coronary | "diseases" : "Coronary Artery Disease", | ||
"abbreviation" : "CIRT", | "abbreviation" : "CIRT", | ||
"title" : "Low-dose methotrexate for the prevention of atherosclerotic events", | "title" : "Low-dose methotrexate for the prevention of atherosclerotic events", | ||
Line 3,992: | Line 3,992: | ||
"title" : "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", | "title" : "Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes", | ||
"pmid" : "33264825" | "pmid" : "33264825" | ||
}, | |||
{ | |||
"timestamp" : "2025-05-22T17:37:48Z", | |||
"briefDesignDescription" : "Lifestyle interventions to prevent diabetes", | |||
"fulltexturl" : "http://www.nejm.org/doi/full/10.1056/NEJM200105033441801#t", | |||
"pageid" : 2776, | |||
"pdfurl" : "http://www.nejm.org/doi/pdf/10.1056/NEJM200105033441801", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Tuomilehto J, <i>et al</i>. \"Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance\". <i>The New England Journal of Medicine</i>. 2001. 344(18):1343-1350.", | |||
"subspecialties" : "Endocrinology", | |||
"expansion" : "", | |||
"statusUsableDate" : "2025-06-01", | |||
"briefResultsDescription" : "Intensive lifestyle interventions prevent diabetes", | |||
"published" : "2001-15-03", | |||
"pageName" : "Finnish Diabetes Prevention Study", | |||
"diseases" : "Diabetes Mellitus", | |||
"abbreviation" : "Finnish Diabetes Prevention Study", | |||
"title" : "Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance", | |||
"pmid" : "11333990" | |||
}, | }, | ||
{ | { | ||
Line 4,184: | Line 4,203: | ||
}, | }, | ||
{ | { | ||
"timestamp" : " | "timestamp" : "2025-05-22T17:32:19Z", | ||
"briefDesignDescription" : "PUFA in patients with heart failure", | "briefDesignDescription" : "PUFA in patients with heart failure", | ||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext", | "fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)61239-8/fulltext", | ||
Line 4,197: | Line 4,216: | ||
"published" : "2008-10-04", | "published" : "2008-10-04", | ||
"pageName" : "GISSI-HF", | "pageName" : "GISSI-HF", | ||
"diseases" : "Heart | "diseases" : "Heart Failure", | ||
"abbreviation" : "GISSI-HF", | "abbreviation" : "GISSI-HF", | ||
"title" : "Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure", | "title" : "Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure", | ||
Line 4,239: | Line 4,258: | ||
"title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | "title" : "Mild Therapeutic Hypothermia to Improve the Neurologic Outcome After Cardiac Arrest", | ||
"pmid" : "11856793" | "pmid" : "11856793" | ||
}, | |||
{ | |||
"timestamp" : "2025-05-22T17:34:50Z", | |||
"briefDesignDescription" : "High- vs. low-dose losartan in heart failure", | |||
"fulltexturl" : "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61913-9/fulltext", | |||
"pageid" : 2825, | |||
"pdfurl" : "http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(09)61913-9.pdf", | |||
"trainingLevel" : "resident", | |||
"citation" : "Konstam MA, <i>et al</i>. \"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure\". <i>The Lancet</i>. 2009. 374(9704):1840-1848.", | |||
"subspecialties" : "Cardiology", | |||
"expansion" : "Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan", | |||
"statusUsableDate" : "2025-05-12", | |||
"briefResultsDescription" : "High-dose losartan improves HF outcomes", | |||
"published" : "2009-11-28", | |||
"pageName" : "HEAAL", | |||
"diseases" : "Heart Failure", | |||
"abbreviation" : "HEAAL", | |||
"title" : "Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure", | |||
"pmid" : "19922995" | |||
}, | }, | ||
{ | { | ||
Line 7,279: | Line 7,317: | ||
"title" : "Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)", | "title" : "Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)", | ||
"pmid" : "17513708" | "pmid" : "17513708" | ||
}, | |||
{ | |||
"timestamp" : "2025-05-22T17:30:01Z", | |||
"briefDesignDescription" : "Delayed vs. early cardioversion in AF", | |||
"fulltexturl" : "https://www.nejm.org/doi/10.1056/NEJMoa1900353", | |||
"pageid" : 4062, | |||
"pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa1900353", | |||
"trainingLevel" : "Resident", | |||
"citation" : "Pluymaekers NAHA, <i>et al</i>. \"Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation\". <i>The New England Journal of Medicine</i>. 2019. 380(16):1499-1508.", | |||
"subspecialties" : "Emergency Medicine;Cardiology", | |||
"expansion" : "Rate Control versus Electrical Cardioversion Trial 7–Acute Cardioversion versus Wait and See", | |||
"statusUsableDate" : "2025-05-25", | |||
"briefResultsDescription" : "Delayed is noninferior to early cardioversion in obtaining sinus rhythm", | |||
"published" : "2019-04-18", | |||
"pageName" : "RACE 7 ACWAS", | |||
"diseases" : "Atrial Fibrillation", | |||
"abbreviation" : "RACE 7 ACWAS", | |||
"title" : "Early or Delayed Cardioversion in Recent-Onset Atrial Fibrillation", | |||
"pmid" : "30883054" | |||
}, | }, | ||
{ | { | ||
Line 7,374: | Line 7,431: | ||
"title" : "Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus", | "title" : "Intramuscular versus Intravenous Therapy for Prehospital Status Epilepticus", | ||
"pmid" : "22335736" | "pmid" : "22335736" | ||
}, | |||
{ | |||
"timestamp" : "2025-05-22T17:14:03Z", | |||
"briefDesignDescription" : "Chemo-RT vs. chemo in rectal cancer", | |||
"fulltexturl" : "https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30555-6/fulltext", | |||
"pageid" : 5600, | |||
"pdfurl" : "https://www.thelancet.com/action/showPdf?pii", | |||
"trainingLevel" : "Fellow", | |||
"citation" : "Bahadoer RR, <i>et al</i>. \"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial\". <i>The Lancet Oncology</i>. 2021. 22(1):29-42.", | |||
"subspecialties" : "Oncology", | |||
"expansion" : "Rectal Cancer and Preoperative Induction Therapy Followed by Dedicated Operation Trial", | |||
"statusUsableDate" : "2025-05-22", | |||
"briefResultsDescription" : "Fewer treatment failures with chemo-RT", | |||
"published" : "2021-01-01", | |||
"pageName" : "RAPIDO", | |||
"diseases" : "Colorectal Cancer", | |||
"abbreviation" : "RAPIDO", | |||
"title" : "Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial", | |||
"pmid" : "33301740" | |||
}, | }, | ||
{ | { |